Michaels PD, Robinson H, Nardi V, Iafrate AJ, Le L, Lennerz JK
International journal of surgical pathology
MET Amplification in Esophageal Squamous Carcinoma. Int J Surg Pathol. 2018 12; 26(8):731-732.
MET Amplification in Esophageal Squamous Carcinoma.
Le Y, Xu L, Lu J, Fang J, Nardi V, Chai L, Silberstein LE
FAK silencing inhibits leukemogenesis in BCR/ABL-transformed hematopoietic cells. Am J Hematol. 2009 May; 84(5):273-8.
FAK silencing inhibits leukemogenesis in BCR/ABL-transformed hematopoietic cells.
Laboratory testing in BCR-ABL1-like (Philadelphia-like) B-lymphoblastic leukemia/lymphoma. Am J Hematol. 2018 07; 93(7):971-977.
Laboratory testing in BCR-ABL1-like (Philadelphia-like) B-lymphoblastic leukemia/lymphoma.
Patel SS, Kuo FC, Gibson CJ, Steensma DP, Soiffer RJ, Alyea EP, Chen YA, Fathi AT, Graubert TA, Brunner AM, Wadleigh M, Stone RM, DeAngelo DJ, Nardi V, Hasserjian RP, Weinberg OK
High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood. 2018 06 21; 131(25):2816-2825.
High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML.
Ng SY, Yoshida N, Christie AL, Ghandi M, Dharia NV, Dempster J, Murakami M, Shigemori K, Morrow SN, Van Scoyk A, Cordero NA, Stevenson KE, Puligandla M, Haas B, Lo C, Meyers R, Gao G, Cherniack A, Louissaint A, Nardi V, Thorner AR, Long H, Qiu X, Morgan EA, Dorfman DM, Fiore D, Jang J, Epstein AL, Dogan A, Zhang Y, Horwitz SM, Jacobsen ED, Santiago S, Ren JG, Guerlavais V, Annis DA, Aivado M, Saleh MN, Mehta A, Tsherniak A, Root D, Vazquez F, Hahn WC, Inghirami G, Aster JC, Weinstock DM, Koch R
Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun. 2018 05 22; 9(1):2024.
Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models.
Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol. 2004 Jan; 11(1):35-43.
Mechanisms and implications of imatinib resistance mutations in BCR-ABL.
Cai A, Keskin DB, DeLuca DS, Alonso A, Zhang W, Zhang GL, Hammond NN, Nardi V, Stone RM, Neuberg D, Sidney J, Brusic V, Wu CJ
Clinical cancer research : an official journal of the American Association for Cancer Research
Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients. Clin Cancer Res. 2012 Oct 15; 18(20):5761-72.
Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients.
Santamaria-Barria JA, Boland GM, Yeap BY, Nardi V, Dias-Santagata D, Cusack JC
Merkel cell carcinoma: 30-year experience from a single institution. Ann Surg Oncol. 2013 Apr; 20(4):1365-73.
Merkel cell carcinoma: 30-year experience from a single institution.
ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines. Blood. 2009 Apr 16; 113(16):3813-20.
ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines.
Shiota H, Elya JE, Alekseyenko AA, Chou PM, Gorman SA, Barbash O, Becht K, Danga K, Kuroda MI, Nardi V, French CA
"Z4" Complex Member Fusions in NUT Carcinoma: Implications for a Novel Oncogenic Mechanism. Mol Cancer Res. 2018 12; 16(12):1826-1833.
"Z4" Complex Member Fusions in NUT Carcinoma: Implications for a Novel Oncogenic Mechanism.
Jeck WR, Lee J, Robinson H, Le LP, Iafrate AJ, Nardi V
The Journal of molecular diagnostics : JMD
A Nanopore Sequencing-Based Assay for Rapid Detection of Gene Fusions. J Mol Diagn. 2019 01; 21(1):58-69.
A Nanopore Sequencing-Based Assay for Rapid Detection of Gene Fusions.
Bennett JA, Pesci A, Morales-Oyarvide V, Da Silva A, Nardi V, Oliva E
The American journal of surgical pathology
Incidence of Mismatch Repair Protein Deficiency and Associated Clinicopathologic Features in a Cohort of 104 Ovarian Endometrioid Carcinomas. Am J Surg Pathol. 2019 02; 43(2):235-243.
Incidence of Mismatch Repair Protein Deficiency and Associated Clinicopathologic Features in a Cohort of 104 Ovarian Endometrioid Carcinomas.
Zomnir MG, Lipkin L, Pacula M, Meneses ED, MacLeay A, Duraisamy S, Nadhamuni N, Al Turki SH, Zheng Z, Rivera M, Nardi V, Dias-Santagata D, Iafrate AJ, Le LP, Lennerz JK
Artificial Intelligence Approach for Variant Reporting. JCO Clin Cancer Inform. 2018; 2.
Artificial Intelligence Approach for Variant Reporting.
Dagogo-Jack I, Azzolli CG, Fintelmann F, Mino-Kenudson M, Farago AF, Gainor JF, Jiang G, Piotrowska Z, Heist RS, Lennes IT, Temel JS, Mooradian MJ, Lin JJ, Digumarthy SR, Batten JM, Robinson H, Nose V, Rivera M, Nardi V, Dias-Santagata D, Le LP, Sequist LV, Pitman M, Shepard JO, Shaw AT, Iafrate AJ, Lennerz JK
Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precis Oncol. 2018; 2018.
Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer.
Chougule A, Taylor MS, Nardi V, Chebib I, Cote GM, Choy E, Nielsen GP, Deshpande V
Spindle and Round Cell Sarcoma With EWSR1-PATZ1 Gene Fusion: A Sarcoma With Polyphenotypic Differentiation. Am J Surg Pathol. 2019 02; 43(2):220-228.
Spindle and Round Cell Sarcoma With EWSR1-PATZ1 Gene Fusion: A Sarcoma With Polyphenotypic Differentiation.
Bardia A, Hovnanian MD, Brachtel EF, Nardi V
Case 35-2018: A 68-Year-Old Woman with Back Pain and a Remote History of Breast Cancer. N Engl J Med. 2018 Nov 15; 379(20):1946-1953.
Case 35-2018: A 68-Year-Old Woman with Back Pain and a Remote History of Breast Cancer.
Troschel FM, Gottumukkala RV, DiCorpo D, Mario J, Ott HC, Wright CD, Muniappan A, Lanuti M, Yang K, Shepard JO, Nardi V, Michaelson JS, Hariri LP, Fintelmann FJ
Archives of pathology & laboratory medicine
Feasibility of Perioperative Micro-Computed Tomography of Human Lung Cancer Specimens: A Pilot Study. Arch Pathol Lab Med. 2019 03; 143(3):319-325.
Feasibility of Perioperative Micro-Computed Tomography of Human Lung Cancer Specimens: A Pilot Study.
Bale TA, Jordan JT, Rapalino O, Ramamurthy N, Jessop N, DeWitt JC, Nardi V, Alvarez MM, Frosch M, Batchelor TT, Louis DN, Iafrate AJ, Cahill DP, Lennerz JK
Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. Neuro Oncol. 2019 05 06; 21(5):596-605.
Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.
Boiocchi L, Hasserjian RP, Pozdnyakova O, Wong WJ, Lennerz JK, Le LP, Dias-Santagata D, Iafrate AJ, Hobbs GS, Nardi V
Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms. Hum Pathol. 2019 04; 86:1-11.
Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms.
Nardi V, Sadow PM, Juric D, Zhao D, Cosper AK, Bergethon K, Scialabba VL, Batten JM, Borger DR, Iafrate AJ, Heist RS, Lawrence DP, Flaherty KT, Bendell JC, Deschler D, Li Y, Wirth LJ, Dias-Santagata D
Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment. Clin Cancer Res. 2013 Jan 15; 19(2):480-90.
Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment.
Thierauf J, Ramamurthy N, Jo VY, Robinson H, Frazier RP, Gonzalez J, Pacula M, Dominguez Meneses E, Nose V, Nardi V, Dias-Santagata D, Le LP, Lin DT, Faquin WC, Wirth LJ, Hess J, Iafrate AJ, Lennerz JK
Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma. Oncologist. 2019 10; 24(10):1356-1367.
Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma.
Case 35-2018: A Woman with Back Pain and a Remote History of Breast Cancer. Reply. N Engl J Med. 2019 04 11; 380(15):e22.
Case 35-2018: A Woman with Back Pain and a Remote History of Breast Cancer. Reply.
Weinberg OK, Hasserjian RP, Baraban E, Ok CY, Geyer JT, Philip JKSS, Kurzer JH, Rogers HJ, Nardi V, Stone RM, Garcia JS, Hsi ED, Bagg A, Wang SA, Orazi A, Arber DA
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. Mod Pathol. 2019 09; 32(9):1373-1385.
Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group.
David G. Nathan Distinguished Professor of Pediatrics
Benjamin Castleman Professor of Pathology
Austin L. Vickery, Jr. Professor of Pathology
Benjamin Castleman Distinguished Professor of Pathology
Richard and Susan Smith Professor of Medicine
Premalignant Clonal Hematopoietic Proliferations. Am J Clin Pathol. 2019 08 01; 152(3):347-358.
Premalignant Clonal Hematopoietic Proliferations.
Krystel-Whittemore M, Taylor MS, Rivera M, Lennerz JK, Le LP, Dias-Santagata D, Iafrate AJ, Deshpande V, Chebib I, Nielsen GP, Wu CL, Nardi V
Novel and established EWSR1 gene fusions and associations identified by next-generation sequencing and fluorescence in-situ hybridization. Hum Pathol. 2019 11; 93:65-73.
Novel and established EWSR1 gene fusions and associations identified by next-generation sequencing and fluorescence in-situ hybridization.
Vivero M, Davineni P, Nardi V, Chan JKC, Sholl LM
Metaplastic thymoma: a distinctive thymic neoplasm characterized by YAP1-MAML2 gene fusions. Mod Pathol. 2020 04; 33(4):560-565.
Metaplastic thymoma: a distinctive thymic neoplasm characterized by YAP1-MAML2 gene fusions.
Case 35-2019: A 66-Year-Old Man with Pancytopenia and Rash. N Engl J Med. 2019 Nov 14; 381(20):1951-1960.
Case 35-2019: A 66-Year-Old Man with Pancytopenia and Rash.
Cummings BM, Shailam R, Rosales AM, Huang MS, Nardi V
Case 37-2019: A 20-Month-Old Boy with Severe Anemia. N Engl J Med. 2019 Nov 28; 381(22):2158-2167.
Case 37-2019: A 20-Month-Old Boy with Severe Anemia.
Brown P, Inaba H, Annesley C, Beck J, Colace S, Dallas M, DeSantes K, Kelly K, Kitko C, Lacayo N, Larrier N, Maese L, Mahadeo K, Nanda R, Nardi V, Rodriguez V, Rossoff J, Schuettpelz L, Silverman L, Sun J, Sun W, Teachey D, Wong V, Yanik G, Johnson-Chilla A, Ogba N
Journal of the National Comprehensive Cancer Network : JNCCN
Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 01; 18(1):81-112.
Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
Nardi V, Ku N, Frigault MJ, Dubuc AM, Tsai HK, Amrein PC, Hobbs GS, Brunner AM, Narayan R, Burke ME, Foster J, Dal Cin P, Maus MV, Fathi AT, Hock H
Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement. Blood Adv. 2020 01 14; 4(1):106-111.
Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement.
Jan M, Grinshpun DE, Villalba JA, Dal Cin P, Sykes DB, Iafrate AJ, Ebert BL, Hobbs GS, Nardi V
A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia. Blood Adv. 2020 02 11; 4(3):445-448.
A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia.
Ouseph MM, Hasserjian RP, Dal Cin P, Lovitch SB, Steensma DP, Nardi V, Weinberg OK
Genomic alterations in patients with somatic loss of the Y chromosome as the sole cytogenetic finding in bone marrow cells. Haematologica. 2021 02 01; 106(2):555-564.
Genomic alterations in patients with somatic loss of the Y chromosome as the sole cytogenetic finding in bone marrow cells.
Sykes DB, Zhang EW, Karp Leaf RS, Nardi V, Turbett SE
Case 10-2020: An 83-Year-Old Man with Pancytopenia and Acute Renal Failure. N Engl J Med. 2020 03 26; 382(13):1258-1266.
Case 10-2020: An 83-Year-Old Man with Pancytopenia and Acute Renal Failure.
Chau NG, Ma C, Danga K, Al-Sayegh H, Nardi V, Barrette R, Lathan CS, DuBois SG, Haddad RI, Shapiro GI, Sallan SE, Dhar A, Nelson JJ, French CA
An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients. JNCI Cancer Spectr. 2020 Apr; 4(2):pkz094.
An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients.
Ciammaichella A, Ferrigno F, Basta A, D'Amico M, Biancofiore I, Nardi V, Ponzi S, Graziani R, Gennari N, Vittoria Orsale M, Fini I, Paonessa G, Summa V, Harper S, Ontoria JM
Bioorganic & medicinal chemistry letters
Optimization of 2-(1H-imidazo-2-yl)piperazines series of Trypanosoma brucei growth inhibitors as potential treatment for the second stage of HAT. Bioorg Med Chem Lett. 2020 06 15; 30(12):127207.
Optimization of 2-(1H-imidazo-2-yl)piperazines series of Trypanosoma brucei growth inhibitors as potential treatment for the second stage of HAT.
Hung YP, Diaz-Perez JA, Cote GM, Wejde J, Schwab JH, Nardi V, Chebib IA, Deshpande V, Selig MK, Bredella MA, Rosenberg AE, Nielsen GP
Dedifferentiated Chordoma: Clinicopathologic and Molecular Characteristics With Integrative Analysis. Am J Surg Pathol. 2020 09; 44(9):1213-1223.
Dedifferentiated Chordoma: Clinicopathologic and Molecular Characteristics With Integrative Analysis.
Massoth LR, Hung YP, Nardi V, Nielsen GP, Hasserjian RP, Louissaint A, Fisch AS, Deshpande V, Zukerberg LR, Lennerz JK, Selig M, Glomski K, Patel PJ, Williams KJ, Sokol ES, Alexander BM, Vergilio JA, Ross JS, Pavlick DC, Chebib I, Williams EA
Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1-KMT2A-YAP1 and VIM-KMT2A fusions. Mod Pathol. 2020 11; 33(11):2307-2317.
Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1-KMT2A-YAP1 and VIM-KMT2A fusions.
Tsai HK, Brackett DG, Szeto D, Frazier R, MacLeay A, Davineni P, Manning DK, Garcia E, Lindeman NI, Le LP, Lennerz JK, Gibson CJ, Lindsley RC, Kim AS, Nardi V
Targeted Informatics for Optimal Detection, Characterization, and Quantification of FLT3 Internal Tandem Duplications Across Multiple Next-Generation Sequencing Platforms. J Mol Diagn. 2020 09; 22(9):1162-1178.
Targeted Informatics for Optimal Detection, Characterization, and Quantification of FLT3 Internal Tandem Duplications Across Multiple Next-Generation Sequencing Platforms.
Kasbekar M, Nardi V, Dal Cin P, Brunner AM, Burke M, Chen YB, Connolly C, Fathi AT, Foster J, Macrae M, McAfee SL, McGregor K, Narayan R, Ramos AY, Som TT, Vartanian M, Friedman RS, Benhadji KA, Hobbs GS
Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia. Blood Adv. 2020 07 14; 4(13):3136-3140.
Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia.
Venkataraman V, Casey KS, Onozato M, Cin PD, Nardi V, Amrein PC, Bergeron MK, Brunner AM, Fathi AT, Foster JE, Moran J, Graubert TA, Hock H, Hunnewell C, Frigault MJ, McAfee S, Hobbs GS
Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy. Leukemia. 2020 11; 34(11):3050-3054.
Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy.
Miller TE, Garcia Beltran WF, Bard AZ, Gogakos T, Anahtar MN, Astudillo MG, Yang D, Thierauf J, Fisch AS, Mahowald GK, Fitzpatrick MJ, Nardi V, Feldman J, Hauser BM, Caradonna TM, Marble HD, Ritterhouse LL, Turbett SE, Batten J, Georgantas NZ, Alter G, Schmidt AG, Harris JB, Gelfand JA, Poznansky MC, Bernstein BE, Louis DN, Dighe A, Charles RC, Ryan ET, Branda JA, Pierce VM, Murali MR, Iafrate AJ, Rosenberg ES, Lennerz JK
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
Clinical sensitivity and interpretation of PCR and serological COVID-19 diagnostics for patients presenting to the hospital. FASEB J. 2020 10; 34(10):13877-13884.
Clinical sensitivity and interpretation of PCR and serological COVID-19 diagnostics for patients presenting to the hospital.
Massoth LR, Hung YP, Dias-Santagata D, Onozato M, Shah N, Severson E, Duncan D, Gillespie BJ, Williams NF, Ross JS, Vergilio JA, Harkins SK, Glomski K, Nardi V, Zukerberg LR, Hasserjian RP, Louissaint A, Williams EA
Pan-Cancer Landscape Analysis Reveals Recurrent KMT2A-MAML2 Gene Fusion in Aggressive Histologic Subtypes of Thymoma. JCO Precis Oncol. 2020; 4.
Pan-Cancer Landscape Analysis Reveals Recurrent KMT2A-MAML2 Gene Fusion in Aggressive Histologic Subtypes of Thymoma.
Makhdoum S, Nardi V, Devereaux KA, Kunder CA, Nielsen GP, Oliva E, Young RH, Roberts DJ
Inflammatory myofibroblastic tumors associated with the placenta: a series of 9 cases. Hum Pathol. 2020 12; 106:62-73.
Inflammatory myofibroblastic tumors associated with the placenta: a series of 9 cases.
Lin JJ, Liu SV, McCoach CE, Zhu VW, Tan AC, Yoda S, Peterson J, Do A, Prutisto-Chang K, Dagogo-Jack I, Sequist LV, Wirth LJ, Lennerz JK, Hata AN, Mino-Kenudson M, Nardi V, Ou SI, Tan DS, Gainor JF
Annals of oncology : official journal of the European Society for Medical Oncology
Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Ann Oncol. 2020 12; 31(12):1725-1733.
Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
Tratwal J, Bekri D, Boussema C, Sarkis R, Kunz N, Koliqi T, Rojas-Sutterlin S, Schyrr F, Tavakol DN, Campos V, Scheller EL, Sarro R, Bárcena C, Bisig B, Nardi V, de Leval L, Burri O, Naveiras O
MarrowQuant Across Aging and Aplasia: A Digital Pathology Workflow for Quantification of Bone Marrow Compartments in Histological Sections. Front Endocrinol (Lausanne). 2020; 11:480.
MarrowQuant Across Aging and Aplasia: A Digital Pathology Workflow for Quantification of Bone Marrow Compartments in Histological Sections.
Crotty R, Hu K, Stevenson K, Pontius MY, Sohani AR, Ryan RJH, Rueckert E, Brauer HA, Hudson B, Berlin AM, Rodenbaugh M, Licon A, Haimes J, Iafrate AJ, Nardi V, Louissaint A
Simultaneous Identification of Cell of Origin, Translocations, and Hotspot Mutations in Diffuse Large B-Cell Lymphoma Using a Single RNA-Sequencing Assay. Am J Clin Pathol. 2021 04 26; 155(5):748-754.
Simultaneous Identification of Cell of Origin, Translocations, and Hotspot Mutations in Diffuse Large B-Cell Lymphoma Using a Single RNA-Sequencing Assay.
Hung YP, Fisch AS, Diaz-Perez JA, Iafrate AJ, Lennerz JK, Nardi V, Bredella MA, Raskin KA, Lozano-Calderon SA, Rosenberg AE, Nielsen GP
Identification of EWSR1-NFATC2 fusion in simple bone cysts. Histopathology. 2021 May; 78(6):849-856.
Identification of EWSR1-NFATC2 fusion in simple bone cysts.
Nanopore Flongle Sequencing as a Rapid, Single-Specimen Clinical Test for Fusion Detection. J Mol Diagn. 2021 05; 23(5):630-636.
Nanopore Flongle Sequencing as a Rapid, Single-Specimen Clinical Test for Fusion Detection.
Plasma cell myeloma: role of histopathology, immunophenotyping, and genetic testing. Skeletal Radiol. 2022 Jan; 51(1):17-30.
Plasma cell myeloma: role of histopathology, immunophenotyping, and genetic testing.
Predictive 'biomarker piggybacking': an examination of reflexive pan-cancer screening with pan-TRK immunohistochemistry. Histopathology. 2021 Aug; 79(2):260-264.
Predictive 'biomarker piggybacking': an examination of reflexive pan-cancer screening with pan-TRK immunohistochemistry.
Massoth LR, Hung YP, Ferry JA, Hasserjian RP, Nardi V, Nielsen GP, Sadigh S, Venkataraman V, Selig M, Friedmann AM, Samore W, Killian JK, Milante R, Giessinger J, Foley-Peres K, Marcus C, Severson E, Duncan D, Sivakumar S, Ross JS, Desphande V, Ramkissoon SH, Vergilio JA, Louissaint A, Zukerberg LR, Williams EA
Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma. Oncologist. 2021 07; 26(7):e1263-e1272.
Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma.
Tang G, Tam W, Short NJ, Bose P, Wu D, Hurwitz SN, Bagg A, Rogers HJ, Hsi ED, Quesada AE, Wang W, Miranda RN, Bueso-Ramos CE, Medeiros LJ, Nardi V, Hasserjian RP, Arber DA, Orazi A, Foucar K, Wang SA
Myeloid/lymphoid neoplasms with FLT3 rearrangement. Mod Pathol. 2021 09; 34(9):1673-1685.
Myeloid/lymphoid neoplasms with FLT3 rearrangement.
Shepherd DJ, Miller TE, Forst DA, Jones P, Nardi V, Martinez-Lage M, Stemmer-Rachamimov A, Gonzalez RG, Iafrate AJ, Ritterhouse LL
Mosaicism for Receptor Tyrosine Kinase Activation in a Glioblastoma Involving Both PDGFRA Amplification and NTRK2 Fusion. Oncologist. 2021 11; 26(11):919-924.
Mosaicism for Receptor Tyrosine Kinase Activation in a Glioblastoma Involving Both PDGFRA Amplification and NTRK2 Fusion.
Ordulu Z, Avril S, Nardi V, Dias-Santagata D, Oliva E
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
Low-grade Endometrial Stromal Sarcoma With Sex Cord-like Differentiation and PHF1-JAZF1 Fusion With Deletions: A Diagnostic Pitfall of JAZF1 FISH. Int J Gynecol Pathol. 2022 May 01; 41(3):244-250.
Low-grade Endometrial Stromal Sarcoma With Sex Cord-like Differentiation and PHF1-JAZF1 Fusion With Deletions: A Diagnostic Pitfall of JAZF1 FISH.
Chebib I, Taylor MS, Nardi V, Rivera MN, Lennerz JK, Cote GM, Choy E, Lozano Calderón SA, Raskin KA, Schwab JH, Mullen JT, Chen YE, Hung YP, Nielsen GP, Deshpande V
Clinical Utility of Anchored Multiplex Solid Fusion Assay for Diagnosis of Bone and Soft Tissue Tumors. Am J Surg Pathol. 2021 08 01; 45(8):1127-1137.
Clinical Utility of Anchored Multiplex Solid Fusion Assay for Diagnosis of Bone and Soft Tissue Tumors.
Fitzpatrick MJ, Massoth LR, Marcus C, Vergilio JA, Severson E, Duncan D, Ramkissoon SH, Hasserjian RP, Kim AS, Sohani AR, Williams EA, Nardi V
JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology. Am J Surg Pathol. 2021 07 01; 45(7):895-904.
JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology.
Leiva O, Baker O, Jenkins A, Brunner AM, Al-Samkari H, Leaf RK, Rosovsky RP, Fathi AT, Weitzman J, Bornikova L, Nardi V, Hobbs GS
Association of Thrombosis With Hypereosinophilic Syndrome in Patients With Genetic Alterations. JAMA Netw Open. 2021 08 02; 4(8):e2119812.
Association of Thrombosis With Hypereosinophilic Syndrome in Patients With Genetic Alterations.
Wang SA, Ok CY, Kim AS, Lucas F, Morgan EA, Thakral B, Patel S, Nardi V, Patel KM, Weinberg OK, Hasserjian RP
Myelodysplastic syndromes with no somatic mutations detected by next-generation sequencing display similar features to myelodysplastic syndromes with detectable mutations. Am J Hematol. 2021 11 01; 96(11):E420-E423.
Myelodysplastic syndromes with no somatic mutations detected by next-generation sequencing display similar features to myelodysplastic syndromes with detectable mutations.
Two In Cis Variants-Two Worlds Apart. Oncologist. 2021 12; 26(12):997-999.
Lee K, Evans MG, Yang L, Ng S, Snowden C, Khodadoust M, Brown RA, Trum NA, Querfeld C, Doan LT, Song J, Zhang H, Gru AA, Wood GS, Wada DA, Shanmugam V, Haun PL, Aster JC, Duncan LM, Guitart J, Weinstock DM, Nardi V, Choi J
Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway. Blood. 2021 12 09; 138(23):2435-2440.
Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway.
Nardi V, Tsuchiya KD, Kim AS, Bean LJH, Halley JG, Long TA, Szelinger S, Vasalos P, Thorson JA, Moyer AM, Moncur JT
Next-Generation Sequencing Somatic and Germline Assay Troubleshooting Guide Derived From Proficiency Testing Data. Arch Pathol Lab Med. 2022 04 01; 146(4):451-461.
Next-Generation Sequencing Somatic and Germline Assay Troubleshooting Guide Derived From Proficiency Testing Data.
Mueller SB, Dal Cin P, Le LP, Dias-Santagata D, Lennerz JK, Iafrate AJ, Marble HD, Brunner AM, Weinstock MJ, Luskin MR, De Angelo DJ, Stone RM, Nardi V
t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity. Blood Adv. 2022 01 08; 6(3):818-827.
t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity.
Yabe M, Omarbekova AZ, Hsu M, May H, Arcila ME, Liu Y, Dogan A, Brunner AM, Nardi V, Hasserjian RP, Klimek VM
TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes. Cancers (Basel). 2021 Nov 02; 13(21).
TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes.
Medford A, Brunner A, Nardi V, Hasserjian R, Carlson J, Choy E
Therapy-Related Erythroleukemia in a Man With Metastatic Ewing Sarcoma: A Clinical Role for Advanced Molecular Diagnostics. JCO Precis Oncol. 2018 Nov; 2:1-6.
Therapy-Related Erythroleukemia in a Man With Metastatic Ewing Sarcoma: A Clinical Role for Advanced Molecular Diagnostics.
An unusual lymphoma involving the GI tract and bone marrow. Am J Hematol. 2022 09; 97(9):1268-1269.
An unusual lymphoma involving the GI tract and bone marrow.
The American Journal of dermatopathology
Gamma/Delta (?d) T Cells: The Role of the T-Cell Receptor in Diagnosis and Prognosis of Hematologic Malignancies. Am J Dermatopathol. 2022 Apr 01; 44(4):237-248.
Gamma/Delta (?d) T Cells: The Role of the T-Cell Receptor in Diagnosis and Prognosis of Hematologic Malignancies.
Wander SA, Hasserjian RP, Oduro K, Glomski K, Nardi V, Cote GM, Graubert TA, Brunner AM, Chen YA, Fathi AT
Combined Targeted Therapy for BRAF-Mutant, Treatment-Related Acute Myeloid Leukemia. JCO Precis Oncol. 2017 Nov; 1:1-7.
Combined Targeted Therapy for BRAF-Mutant, Treatment-Related Acute Myeloid Leukemia.
Bedside to Bench and Back: Identifying a New Clinically Relevant Driver in Pediatric Acute Myeloid Leukemia. Blood Cancer Discov. 2022 05 05; 3(3):173-175.
Bedside to Bench and Back: Identifying a New Clinically Relevant Driver in Pediatric Acute Myeloid Leukemia.
Siegele BJ, Stemmer-Rachamimov AO, Lilljebjorn H, Fioretos T, Winters AC, Dal Cin P, Treece A, Gaskell A, Nardi V
N-terminus DUX4-immunohistochemistry is a reliable methodology for the diagnosis of DUX4-fused B-lymphoblastic leukemia/lymphoma (N-terminus DUX4 IHC for DUX4-fused B-ALL). Genes Chromosomes Cancer. 2022 08; 61(8):449-458.
N-terminus DUX4-immunohistochemistry is a reliable methodology for the diagnosis of DUX4-fused B-lymphoblastic leukemia/lymphoma (N-terminus DUX4 IHC for DUX4-fused B-ALL).
Evans MG, Shestakova A, Haghighi N, Zhao X, Nardi V, Pinter-Brown LC, Rezk SA
Rare case of leptomeningeal small lymphocytic lymphoma with TP53 mutation detected by deep next-generation sequencing. Leuk Lymphoma. 2022 Oct; 63(10):2479-2483.
Rare case of leptomeningeal small lymphocytic lymphoma with TP53 mutation detected by deep next-generation sequencing.
Thierauf JC, Farahani AA, Indave BI, Bard AZ, White VA, Smith CR, Marble H, Hyrcza MD, Chan JKC, Bishop J, Shi Q, Ely K, Agaimy A, Martinez-Lage M, Nose V, Rivera M, Nardi V, Dias-Santagata D, Garg S, Sadow P, Le LP, Faquin W, Ritterhouse LL, Cree IA, Iafrate AJ, Lennerz JK
International journal of molecular sciences
Diagnostic Value of MAML2 Rearrangements in Mucoepidermoid Carcinoma. Int J Mol Sci. 2022 Apr 13; 23(8).
Diagnostic Value of MAML2 Rearrangements in Mucoepidermoid Carcinoma.
Saliba J, Church AJ, Rao S, Danos A, Furtado LV, Laetsch T, Zhang L, Nardi V, Lin WH, Ritter DI, Madhavan S, Li MM, Griffith OL, Griffith M, Raca G, Roy A
Standardized evidence-based approach for assessment of oncogenic and clinical significance of NTRK fusions. Cancer Genet. 2022 06; 264-265:50-59.
Standardized evidence-based approach for assessment of oncogenic and clinical significance of NTRK fusions.
Tsai HK, Gibson CJ, Murdock HM, Davineni P, Harris MH, Wang ES, Gondek LP, Kim AS, Nardi V, Lindsley RC
Allelic complexity of KMT2A partial tandem duplications in acute myeloid leukemia and myelodysplastic syndromes. Blood Adv. 2022 07 26; 6(14):4236-4240.
Allelic complexity of KMT2A partial tandem duplications in acute myeloid leukemia and myelodysplastic syndromes.
Dias-Santagata D, Heist RS, Bard AZ, da Silva AFL, Dagogo-Jack I, Nardi V, Ritterhouse LL, Spring LM, Jessop N, Farahani AA, Mino-Kenudson M, Allen J, Goyal L, Parikh A, Misdraji J, Shankar G, Jordan JT, Martinez-Lage M, Frosch M, Graubert T, Fathi AT, Hobbs GS, Hasserjian RP, Raje N, Abramson J, Schwartz JH, Sullivan RJ, Miller D, Hoang MP, Isakoff S, Ly A, Bouberhan S, Watkins J, Oliva E, Wirth L, Sadow PM, Faquin W, Cote GM, Hung YP, Gao X, Wu CL, Garg S, Rivera M, Le LP, John Iafrate A, Juric D, Hochberg EP, Clark J, Bardia A, Lennerz JK
Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network. Oncologist. 2022 11 03; 27(11):930-939.
Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network.
Fitzpatrick MJ, Boiocchi L, Fathi AT, Brunner AM, Hasserjian RP, Nardi V
Correlation of p53 immunohistochemistry with TP53 mutational status and overall survival in newly diagnosed acute myeloid leukaemia. Histopathology. 2022 Oct; 81(4):496-510.
Correlation of p53 immunohistochemistry with TP53 mutational status and overall survival in newly diagnosed acute myeloid leukaemia.
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS, de Jong D, Du MQ, Elenitoba-Johnson KS, Ferry J, Geyer J, Gratzinger D, Guitart J, Gujral S, Harris M, Harrison CJ, Hartmann S, Hochhaus A, Jansen PM, Karube K, Kempf W, Khoury J, Kimura H, Klapper W, Kovach AE, Kumar S, Lazar AJ, Lazzi S, Leoncini L, Leung N, Leventaki V, Li XQ, Lim MS, Liu WP, Louissaint A, Marcogliese A, Medeiros LJ, Michal M, Miranda RN, Mitteldorf C, Montes-Moreno S, Morice W, Nardi V, Naresh KN, Natkunam Y, Ng SB, Oschlies I, Ott G, Parrens M, Pulitzer M, Rajkumar SV, Rawstron AC, Rech K, Rosenwald A, Said J, Sarkozy C, Sayed S, Saygin C, Schuh A, Sewell W, Siebert R, Sohani AR, Tooze R, Traverse-Glehen A, Vega F, Vergier B, Wechalekar AD, Wood B, Xerri L, Xiao W
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022 07; 36(7):1720-1748.
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.
Moran JMT, Le LP, Nardi V, Golas J, Farahani AA, Signorelli S, Onozato ML, Foreman RK, Duncan LM, Lawrence DP, Lennerz JK, Dias-Santagata D, Hoang MP
Identification of fusions with potential clinical significance in melanoma. Mod Pathol. 2022 12; 35(12):1837-1847.
Identification of fusions with potential clinical significance in melanoma.
Soumerai JD, Rosenthal A, Harkins S, Duffy J, Mecca C, Wang Y, Grewal RK, El-Jawahri AR, Liu H, Menard C, Dogan A, Yang L, Rimsza LM, Bantilan K, Martin H, Lei M, Mohr S, Kurilovich A, Kudryashova O, Postovalova E, Nardi V, Abramson JS, Chiarle R, Zelenetz AD, Louissaint A
Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma. Blood. 2022 10 20; 140(16):1822-1826.
Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma.
Nardi V, McAfee SL, Dal Cin P, Tsai HK, Amrein PC, Hobbs GS, Brunner AM, Narayan R, Foster J, Fathi AT, Hock H
Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and Immunotherapy. Oncologist. 2022 03 04; 27(2):82-86.
Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and Immunotherapy.
Molecular Detection of Oncogenic Gene Rearrangements. Clin Lab Med. 2022 09; 42(3):435-449.
Molecular Detection of Oncogenic Gene Rearrangements.
Ordulu Z, Mino-Kenudson M, Young RH, Van de Vijver K, Zannoni GF, Félix A, Burandt E, Wong A, Nardi V, Oliva E
Morphologic and Molecular Heterogeneity of Cervical Neuroendocrine Neoplasia: A Report of 14 Cases. Am J Surg Pathol. 2022 12 01; 46(12):1670-1681.
Morphologic and Molecular Heterogeneity of Cervical Neuroendocrine Neoplasia: A Report of 14 Cases.
Response to "Expanding the Clinicopathologic Spectrum of YAP1-MAML2-Rearranged Thymic Neoplasm". Mod Pathol. 2023 03; 36(3):100090.
Response to "Expanding the Clinicopathologic Spectrum of YAP1-MAML2-Rearranged Thymic Neoplasm".
Sarkis R, Burri O, Royer-Chardon C, Schyrr F, Blum S, Costanza M, Cherix S, Piazzon N, Barcena C, Bisig B, Nardi V, Sarro R, Ambrosini G, Weigert M, Spertini O, Blum S, Deplancke B, Seitz A, de Leval L, Naveiras O
MarrowQuant 2.0: A Digital Pathology Workflow Assisting Bone Marrow Evaluation in Experimental and Clinical Hematology. Mod Pathol. 2023 04; 36(4):100088.
MarrowQuant 2.0: A Digital Pathology Workflow Assisting Bone Marrow Evaluation in Experimental and Clinical Hematology.
Tsai HK, Gogakos T, Lip V, Tsai JM, Li YD, Fisch AS, Weiss J, Yang W, Grimmett L, DiToro D, Schaefer EJ, Lindsley RC, Tran TH, Caron M, Langlois S, Sinnett D, Pikman Y, Nardi V, Kim AS, Silverman LB, Harris MH
Outlier Expression of Isoforms by Targeted or Total RNA Sequencing Identifies Clinically Significant Genomic Variants in Hematolymphoid Tumors. J Mol Diagn. 2023 09; 25(9):665-681.
Outlier Expression of Isoforms by Targeted or Total RNA Sequencing Identifies Clinically Significant Genomic Variants in Hematolymphoid Tumors.
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, de Oliveira Araujo IB, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS, de Jong D, Di Napoli A, Du MQ, Elenitoba-Johnson KS, Ferry J, Geyer J, Gratzinger D, Guitart J, Gujral S, Harris M, Harrison CJ, Hartmann S, Hochhaus A, Jansen PM, Karube K, Kempf W, Khoury J, Kimura H, Klapper W, Kovach AE, Kumar S, Lazar AJ, Lazzi S, Leoncini L, Leung N, Leventaki V, Li XQ, Lim MS, Liu WP, Louissaint A, Marcogliese A, Medeiros LJ, Michal M, Miranda RN, Mitteldorf C, Montes-Moreno S, Morice W, Nardi V, Naresh KN, Natkunam Y, Ng SB, Oschlies I, Ott G, Parrens M, Pulitzer M, Rajkumar SV, Rawstron AC, Rech K, Rosenwald A, Said J, Sarkozy C, Sayed S, Saygin C, Schuh A, Sewell W, Siebert R, Sohani AR, Suzuki R, Tooze R, Traverse-Glehen A, Vega F, Vergier B, Wechalekar AD, Wood B, Xerri L, Xiao W
Correction: "The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms" Leukemia. 2022 Jul;36(7):1720-1748. Leukemia. 2023 Sep; 37(9):1944-1951.
Correction: "The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms" Leukemia. 2022 Jul;36(7):1720-1748.
Molecular Diagnostics of Plasma Cell Neoplasms. Surg Pathol Clin. 2023 Jun; 16(2):401-410.
Molecular Diagnostics of Plasma Cell Neoplasms.
Singh H, Keller RB, Kapner KS, Dilly J, Raghavan S, Yuan C, Cohen EF, Tolstorukov M, Andrews E, Brais LK, da Silva A, Perez K, Rubinson DA, Surana R, Giannakis M, Ng K, Clancy TE, Yurgelun MB, Schlechter BL, Clark JW, Shapiro GI, Rosenthal MH, Hornick JL, Nardi V, Li YY, Gupta H, Cherniack AD, Meyerson M, Cleary JM, Nowak JA, Wolpin BM, Aguirre AJ
Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer. Clin Cancer Res. 2023 11 14; 29(22):4627-4643.
Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer.
Dagogo-Jack I, Manoogian A, Jessop N, Georgantas NZ, Fintelmann FJ, Farahani A, Digumarthy SR, Price MC, Folch EE, Keyes CM, Do A, Peterson JL, Mino-Kenudson M, Pitman M, Rivera M, Nardi V, Dias-Santagata D, Le LP, Iafrate AJ, Heist RS, Ritterhouse LR, Lennerz JK
Integrated Radiology, Pathology, and Pharmacy Program to Accelerate Access to Osimertinib. JCO Oncol Pract. 2023 09; 19(9):786-792.
Integrated Radiology, Pathology, and Pharmacy Program to Accelerate Access to Osimertinib.
Zehir A, Nardi V, Konnick EQ, Lockwood CM, Long TA, Sidiropoulos N, Souers RJ, Vasalos P, Lindeman NI, Moncur JT
SPOT/Dx Pilot Reanalysis and College of American Pathologists Proficiency Testing for KRAS and NRAS Demonstrate Excellent Laboratory Performance. Arch Pathol Lab Med. 2024 02 01; 148(2):139-148.
SPOT/Dx Pilot Reanalysis and College of American Pathologists Proficiency Testing for KRAS and NRAS Demonstrate Excellent Laboratory Performance.
Gandhi MM, Ricciuti B, Harada G, Repetto M, Gildenberg MS, Singh A, Li YY, Gagné A, Wang X, Aizer A, Fitzgerald K, Nishino M, Alessi J, Pecci F, Di Federico A, Fisch A, Drilon A, Nardi V, Sholl L, Awad MM, Rotow J
Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib. JCO Precis Oncol. 2023 09; 7:e2300295.
Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib.
Bendapudi PK, Nazeen S, Ryu J, Söylemez O, Robbins A, Rouaisnel B, O'Neil JK, Pokhriyal R, Yang M, Colling M, Pasko B, Bouzinier M, Tomczak L, Collier L, Barrios D, Ram S, Toth-Petroczy A, Krier J, Fieg E, Dzik WH, Hudspeth JC, Pozdnyakova O, Nardi V, Knight J, Maas R, Sunyaev S, Losman JA
Low-frequency inherited complement receptor variants are associated with purpura fulminans. Blood. 2024 03 14; 143(11):1032-1044.
Low-frequency inherited complement receptor variants are associated with purpura fulminans.
Tsai HK, Sabbagh MF, Montesion M, Williams EA, Arbini A, Boué DR, Harris EM, Wachter F, Grimmett L, Place AE, Lucas F, Nardi V, Kim AS, Brugnara C, Degar B, Pollard J, Harris MH, Bledsoe JR
Acute Promyelocytic Leukemia With Torque Teno Mini Virus::RARA Fusion: An Approach to Screening and Diagnosis. Mod Pathol. 2024 Jul; 37(7):100509.
Acute Promyelocytic Leukemia With Torque Teno Mini Virus::RARA Fusion: An Approach to Screening and Diagnosis.
Frigault MJ, Graham CE, Berger TR, Ritchey J, Horick NK, El-Jawahri A, Scarfò I, Schmidts A, Haradhvala NJ, Wehrli M, Lee WH, Parker AL, Wiggin HR, Bouffard A, Dey A, Leick MB, Katsis K, Elder EL, Dolaher MA, Cook DT, Chekmasova AA, Huang L, Nikiforow S, Daley H, Ritz J, Armant M, Preffer F, DiPersio JF, Nardi V, Chen YB, Gallagher KME, Maus MV
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies. Blood. 2024 09 12; 144(11):1153-1167.
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies.
Prior D, Schmitt AD, Louissaint A, Mata DA, Massaro S, Nardi V, Xu ML
Large B-cell lymphoma with mystery rearrangement: Applying Hi-C to the detection of clinically relevant structural abnormalities. Br J Haematol. 2024 Sep; 205(3):1225-1229.
Large B-cell lymphoma with mystery rearrangement: Applying Hi-C to the detection of clinically relevant structural abnormalities.
Sabbagh MF, Janovitz T, Dias-Santagata D, Siegmund S, Nardi V, Wirth LJ, Randolph GW, Lennerz JK, Decker B, Nose V, Alzumaili BA, Faquin WC, Barletta JA, Le LP, Iafrate AJ, Sadow PM, Fisch AS
Thyroid : official journal of the American Thyroid Association
FGFR Alterations in Thyroid Carcinoma: A Novel Class of Primary Drivers with Significant Therapeutic Implications and Secondary Molecular Events Potentially Mediating Resistance in Thyroid Malignancy. Thyroid. 2024 09; 34(9):1137-1149.
FGFR Alterations in Thyroid Carcinoma: A Novel Class of Primary Drivers with Significant Therapeutic Implications and Secondary Molecular Events Potentially Mediating Resistance in Thyroid Malignancy.
A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC. J Hematol Oncol. 2024 07 29; 17(1):56.
A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC.
Santoro M, Mattiucci S, Work T, Cimmaruta R, Nardi V, Cipriani P, Bellisario B, Nascetti G
Parasitic infection by larval helminths in Antarctic fishes: pathological changes and impact on the host body condition index. Dis Aquat Organ. 2013 Jul 22; 105(2):139-48.
Parasitic infection by larval helminths in Antarctic fishes: pathological changes and impact on the host body condition index.
Case records of the Massachusetts General Hospital. Case 24-2013. A 53-year-old woman with erythroderma, pruritus, and lymphadenopathy. N Engl J Med. 2013 Aug 08; 369(6):559-69.
Case records of the Massachusetts General Hospital. Case 24-2013. A 53-year-old woman with erythroderma, pruritus, and lymphadenopathy.
Nakamoto-Matsubara R, Nardi V, Horick N, Fukushima T, Han RS, Shome R, Ochi K, Panaroni C, Fulzele K, Rexha F, Branagan AR, Cirstea D, Yee AJ, Scadden DT, Raje NS
Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma. Blood Cancer J. 2024 12 23; 14(1):224.
Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma.
Torres-Cabala CA, Yescas JA, Zhang Y, Huen A, Sumit G, Tefft K, Tang G, Curry JL, Gunther J, Dabaja B, Iyer S, Miranda RN, Choi J, Nardi V
Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma with novel FGFR1 fusion treated with pemigatinib. Blood Adv. 2025 Apr 22; 9(8):1786-1790.
Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma with novel FGFR1 fusion treated with pemigatinib.
Inaba H, Teachey D, Annesley C, Batra S, Beck J, Colace S, Cooper S, Dallas M, Oliveira S, Kelly K, Kitko C, Kohorst M, Kutny M, Lacayo N, Lee-Miller C, Ludwig K, Madden L, Maloney K, Mangum D, Massaro S, McCall D, Morocco P, Muller B, Murphy L, Nardi V, Rossoff J, Schuettpelz L, Shah B, Sun J, Wong V, Yanik G, Awotiwon A, Stehman K
Pediatric Acute Lymphoblastic Leukemia, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 Feb; 23(2):41-62.
Pediatric Acute Lymphoblastic Leukemia, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
Zhao M, Ryall S, Brody SJ, Harris AC, Cabral K, Brownstein C, Kim JC, Smith AC, Dal Cin P, Narayan R, Sikkink K, Schmitt A, Hobbs GS, Fathi AT, Griffin GK, Sait SNJ, Iafrate AJ, Aster JC, Graubert TA, Nardi V, Dubuc AM
Integrative cytogenetic and molecular studies unmask "chromosomal mimicry" in hematologic malignancies. Blood Adv. 2025 Mar 11; 9(5):1003-1012.
Integrative cytogenetic and molecular studies unmask "chromosomal mimicry" in hematologic malignancies.
Bian W, Zhang B, Song Z, Knisbacher BA, Chan YM, Bao C, Xu C, Wang W, Chu AHY, Lu C, Wang H, Bao S, Gong Z, Keung HY, Chow ZM, Zhang Y, Cheuk W, Getz G, Nardi V, Yang M, Cho WCS, Wang J, Chen J, Zheng Z
SplitFusion enables ultrasensitive gene fusion detection and reveals fusion variant-associated tumor heterogeneity. Patterns (N Y). 2025 Feb 14; 6(2):101174.
SplitFusion enables ultrasensitive gene fusion detection and reveals fusion variant-associated tumor heterogeneity.
Chen MY, Rider AB, Ferry JA, Hasserjian RP, Nardi V, Louissaint A, Sohani AR, Yuen LD
Comparison of Immunohistochemistry With Fluorescence In Situ Hybridization for Assessment of CCND1 Rearrangement in Plasma Cell Myeloma. Am J Surg Pathol. 2025 Nov 01; 49(11):1143-1149.
Comparison of Immunohistochemistry With Fluorescence In Situ Hybridization for Assessment of CCND1 Rearrangement in Plasma Cell Myeloma.
Grabiner BC, Nardi V, Birsoy K, Possemato R, Shen K, Sinha S, Jordan A, Beck AH, Sabatini DM
A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov. 2014 May; 4(5):554-63.
A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.
Role of nucleophosmin 1 immunostain in detecting leukemia cutis of acute myeloid leukemia with NPM1 mutation. Am J Clin Pathol. 2025 11 19; 164(5):712-720.
Role of nucleophosmin 1 immunostain in detecting leukemia cutis of acute myeloid leukemia with NPM1 mutation.
Yuen LD, Hasserjian RP, Fathi AT, Luskin MR, Winer ES, Dal Cin P, Kim AS, Lindsley RC, Tsai HK, Nardi V
Strategies for identifying NUP98 rearrangements in adult myeloid neoplasms. Haematologica. 2026 Feb 01; 111(2):518-534.
Strategies for identifying NUP98 rearrangements in adult myeloid neoplasms.
Cirstea D, Gallagher K, King M, Cin PD, Sloan MJ, Maus MV, Raje N, Frigault M, Nardi V
Transdifferentiation From Multiple Myeloma to Myeloid Sarcoma in the Setting of CAR T-Cell Therapy. Clin Lymphoma Myeloma Leuk. 2026 Jan; 26(1):e127-e131.e1.
Transdifferentiation From Multiple Myeloma to Myeloid Sarcoma in the Setting of CAR T-Cell Therapy.
Blumenberg V, Birocchi F, Shih A, Escobar G, Mucci A, Armstrong A, Cirstea DD, Harris DL, Bozym DJ, Puliafito BR, Newcomb RA, Dhawale TM, Johnson PC, El-Jawahri A, Jeffrey R, Barselau A, Li A, Emmanuel-Alejandro E, Cook D, Lindell KA, Luk SO, Chaffee R, Yee AJ, Branagan AR, Raje NS, Graham C, Hammond SP, Bushman FD, Roche AM, Reddy S, McFarland AG, Chen YB, Choi BD, Mount CW, Dougan M, Nardi V, Sohani A, Gallagher KME, Maus MV, Frigault MJ, Leick MB
Ruxolitinib for Ciltacabtagene Autoleucel-Associated Refractory Diarrhea. Blood. 2026 Jan 27.
Ruxolitinib for Ciltacabtagene Autoleucel-Associated Refractory Diarrhea.
Implementing TRBC1 immunohistochemistry in daily pathology practice. Histopathology. 2026 Feb; 88(3):569-571.
Implementing TRBC1 immunohistochemistry in daily pathology practice.
Case records of the Massachusetts General Hospital. Case 28-2014. A 39-year-old man with a rash, headache, fever, nausea, and photophobia. N Engl J Med. 2014 Sep 11; 371(11):1051-60.
Case records of the Massachusetts General Hospital. Case 28-2014. A 39-year-old man with a rash, headache, fever, nausea, and photophobia.
Gandhi RT, Alkasab TK, Nardi V, Branda JA
Case records of the Massachusetts General Hospital. Case 40-2014. A 57-year-old man with inguinal pain, lymphadenopathy, and HIV infection. N Engl J Med. 2014 Dec 25; 371(26):2511-20.
Case records of the Massachusetts General Hospital. Case 40-2014. A 57-year-old man with inguinal pain, lymphadenopathy, and HIV infection.
Cleven AH, Nardi V, Ok CY, Goswami M, Dal Cin P, Zheng Z, Iafrate AJ, Abdul Hamid MA, Wang SA, Hasserjian RP
High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome. Mod Pathol. 2015 Apr; 28(4):552-63.
High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome.
Nardi V, Pulluqi O, Abramson JS, Dal Cin P, Hasserjian RP
Routine conventional karyotyping of lymphoma staging bone marrow samples does not contribute clinically relevant information. Am J Hematol. 2015 Jun; 90(6):529-33.
Routine conventional karyotyping of lymphoma staging bone marrow samples does not contribute clinically relevant information.
O'Donnell E, Mahindra A, Yee AJ, Nardi V, Birrer N, Horick N, Borger D, Finkelstein D, Iafrate JA, Raje N
Clinical Grade "SNaPshot" Genetic Mutation Profiling in Multiple Myeloma. EBioMedicine. 2015 Jan; 2(1):71-3.
Clinical Grade "SNaPshot" Genetic Mutation Profiling in Multiple Myeloma.
Goyal L, Govindan A, Sheth RA, Nardi V, Blaszkowsky LS, Faris JE, Clark JW, Ryan DP, Kwak EL, Allen JN, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Chong DQ, Deshpande V, Borger DR, Iafrate AJ, Bardeesy N, Zheng H, Zhu AX
Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. Oncologist. 2015 Sep; 20(9):1019-27.
Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
Ryan RJ, Drier Y, Whitton H, Cotton MJ, Kaur J, Issner R, Gillespie S, Epstein CB, Nardi V, Sohani AR, Hochberg EP, Bernstein BE
Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma. Cancer Discov. 2015 Oct; 5(10):1058-71.
Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma.
Platt MY, Fathi AT, Borger DR, Brunner AM, Hasserjian RP, Balaj L, Lum A, Yip S, Dias-Santagata D, Zheng Z, Le LP, Graubert TA, Iafrate AJ, Nardi V
Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Mol Diagn. 2015 Nov; 17(6):661-8.
Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Surg Pathol Clin. 2016 Mar; 9(1):143-63.
Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Santini G, De Souza C, Aversa S, Patti C, Tedeschi L, Candela M, Olivieri A, Chisesi T, Rubagotti A, Centurioni R, Nardi V, Congiu M, Gennaro M, Truini M
Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica
A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma: report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group. Braz J Med Biol Res. 2004 May; 37(5):719-28.
A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma: report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group.
Bennett JA, Oliva E, Nardi V, Lindeman N, Ferry JA, Louissaint A
Primary Endometrial Marginal Zone Lymphoma (MALT Lymphoma): A Unique Clinicopathologic Entity. Am J Surg Pathol. 2016 09; 40(9):1217-23.
Primary Endometrial Marginal Zone Lymphoma (MALT Lymphoma): A Unique Clinicopathologic Entity.
Bardia A, Iafrate JA, Sundaresan T, Younger J, Nardi V
Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital. Oncologist. 2016 09; 21(9):1035-40.
Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital.
Courville EL, Yohe S, Chou D, Nardi V, Lazaryan A, Thakral B, Nelson AC, Ferry JA, Sohani AR
EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations. Mod Pathol. 2016 10; 29(10):1200-11.
EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations.
Wirth LJ, Nardi V, Juric D, Cosper AK, Bergethon K, Scialabba V, Borger DR, Iafrate AJ, Ellisen LW, Deschler D, Zhao D, Sadow PM, Dias-Santagata D
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Detection of novel genetic aberrations in salivary duct carcinoma (SDC) by SNaPshot analysis. J Clin Oncol. 2011 May 20; 29(15_suppl):5579.
Detection of novel genetic aberrations in salivary duct carcinoma (SDC) by SNaPshot analysis.
Weinberg OK, Sohani AR, Bhargava P, Nardi V
Diagnostic work-up of acute myeloid leukemia. Am J Hematol. 2017 Mar; 92(3):317-321.
Diagnostic work-up of acute myeloid leukemia.
Boyer DF, McKelvie PA, de Leval L, Edlefsen KL, Ko YH, Aberman ZA, Kovach AE, Masih A, Nishino HT, Weiss LM, Meeker AK, Nardi V, Palisoc M, Shao L, Pittaluga S, Ferry JA, Harris NL, Sohani AR
Fibrin-associated EBV-positive Large B-Cell Lymphoma: An Indolent Neoplasm With Features Distinct From Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation. Am J Surg Pathol. 2017 Mar; 41(3):299-312.
Fibrin-associated EBV-positive Large B-Cell Lymphoma: An Indolent Neoplasm With Features Distinct From Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation.
Goyal L, Zheng H, Yurgelun MB, Abrams TA, Allen JN, Cleary JM, Knowles M, Regan E, Reardon A, Khachatryan A, Jain RK, Nardi V, Borger DR, Duda DG, Zhu AX
A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Cancer. 2017 06 01; 123(11):1979-1988.
A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
Blute ML, Abramson JS, Cronin KC, Nardi V
Case 5-2017. A 19-Year-Old Man with Hematuria and a Retroperitoneal Mass. N Engl J Med. 2017 02 16; 376(7):684-692.
Case 5-2017. A 19-Year-Old Man with Hematuria and a Retroperitoneal Mass.
Raz T, Nardi V, Azam M, Cortes J, Daley GQ
Farnesyl transferase inhibitor resistance probed by target mutagenesis. Blood. 2007 Sep 15; 110(6):2102-9.
Farnesyl transferase inhibitor resistance probed by target mutagenesis.
Administration of vincristine in a patient with Machado-Joseph disease. Oncology. 2012; 82(3):165-7.
Administration of vincristine in a patient with Machado-Joseph disease.
Bennett JA, Nardi V, Rouzbahman M, Morales-Oyarvide V, Nielsen GP, Oliva E
Inflammatory myofibroblastic tumor of the uterus: a clinicopathological, immunohistochemical, and molecular analysis of 13 cases highlighting their broad morphologic spectrum. Mod Pathol. 2017 10; 30(10):1489-1503.
Inflammatory myofibroblastic tumor of the uterus: a clinicopathological, immunohistochemical, and molecular analysis of 13 cases highlighting their broad morphologic spectrum.
Nardi V, Winkfield KM, Ok CY, Niemierko A, Kluk MJ, Attar EC, Garcia-Manero G, Wang SA, Hasserjian RP
Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. J Clin Oncol. 2012 Jul 01; 30(19):2340-7.
Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms.
Ritterhouse LL, Vivero M, Mino-Kenudson M, Sholl LM, Iafrate AJ, Nardi V, Dong F
GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas. Mod Pathol. 2017 12; 30(12):1720-1727.
GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas.
Hung YP, Dong F, Watkins JC, Nardi V, Bueno R, Dal Cin P, Godleski JJ, Crum CP, Chirieac LR
Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma. JAMA Oncol. 2018 Feb 01; 4(2):235-238.
Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma.
Azam M, Raz T, Nardi V, Opitz SL, Daley GQ
A screen to identify drug resistant variants to target-directed anti-cancer agents. Biol Proced Online. 2003; 5:204-210.
A screen to identify drug resistant variants to target-directed anti-cancer agents.
Nardi V, Raz T, Cao X, Wu CJ, Stone RM, Cortes J, Deininger MW, Church G, Zhu J, Daley GQ
Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors. Oncogene. 2008 Jan 31; 27(6):775-82.
Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors.
Nardi V, Song Y, Santamaria-Barria JA, Cosper AK, Lam Q, Faber AC, Boland GM, Yeap BY, Bergethon K, Scialabba VL, Tsao H, Settleman J, Ryan DP, Borger DR, Bhan AK, Hoang MP, Iafrate AJ, Cusack JC, Engelman JA, Dias-Santagata D
Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res. 2012 Mar 01; 18(5):1227-36.
Activation of PI3K signaling in Merkel cell carcinoma.
Ryan RJH, Petrovic J, Rausch DM, Zhou Y, Lareau CA, Kluk MJ, Christie AL, Lee WY, Tarjan DR, Guo B, Donohue LKH, Gillespie SM, Nardi V, Hochberg EP, Blacklow SC, Weinstock DM, Faryabi RB, Bernstein BE, Aster JC, Pear WS
A B Cell Regulome Links Notch to Downstream Oncogenic Pathways in Small B Cell Lymphomas. Cell Rep. 2017 Oct 17; 21(3):784-797.
A B Cell Regulome Links Notch to Downstream Oncogenic Pathways in Small B Cell Lymphomas.
Naveiras O, Nardi V, Wenzel PL, Hauschka PV, Fahey F, Daley GQ
Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature. 2009 Jul 09; 460(7252):259-63.
Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment.
Church AJ, Calicchio ML, Nardi V, Skalova A, Pinto A, Dillon DA, Gomez-Fernandez CR, Manoj N, Haimes JD, Stahl JA, Dela Cruz FS, Tannenbaum-Dvir S, Glade-Bender JL, Kung AL, DuBois SG, Kozakewich HP, Janeway KA, Perez-Atayde AR, Harris MH
Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Mod Pathol. 2018 03; 31(3):463-473.
Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy.
Tse JY, Chan MP, Ferry JA, Deshpande V, Sohani AR, Nardi V, Schaffer A, Nazarian RM, Zukerberg LR
Syphilis of the Aerodigestive Tract. Am J Surg Pathol. 2018 04; 42(4):472-478.
Azam M, Nardi V, Shakespeare WC, Metcalf CA, Bohacek RS, Wang Y, Sundaramoorthi R, Sliz P, Veach DR, Bornmann WG, Clarkson B, Dalgarno DC, Sawyer TK, Daley GQ
Proceedings of the National Academy of Sciences of the United States of America
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc Natl Acad Sci U S A. 2006 Jun 13; 103(24):9244-9.
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.